CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. CTIC today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details:

Event: Cowen 42^nd Annual Healthcare Conference

Date: Monday, March 7, 2022

Time: 1:30 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.

We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^TM is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:

Argot Partners

+212-600-1902

cti@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-cowen-42nd-annual-healthcare-conference-301494288.html

SOURCE CTI BioPharma Corp.